论文部分内容阅读
目的:在我们的前期实验中,我们运用质谱技术研究新鲜培养的结直肠癌和对应的正常黏膜蛋白组学差异时发现基质重建相关蛋白5(MXRA5)在两者之间的表达有明显的差异,而目前并没有关于MXRA5是否可以作为结直肠癌肿瘤标志物的研究;本实验的目的是探索MXRA5在结直肠癌中的表达情况以及其临床意义。方法:运用免疫组化和实时定量PCR技术,对MXRA5在结直肠中的表达情况进行检测,并分析其与临床病理特征的关系。结果:MXRA5在结直肠正常组织、腺瘤和肿瘤中的免疫评分有明显差异(P<0.05),而且MXRA5的阳性表达与肿瘤的分期和大网膜转移明显相关。基因水平MXRA5的表达没有发现明显差异。结论:我们的研究结果证实了MXRA5在肠癌组织中存在异常表达,并且可能是结直肠癌早期诊断或者大网膜转移的肿瘤标志物。
OBJECTIVE: In our previous experiment, we used mass spectrometry to study the difference in proteomics between freshly cultured colorectal cancer and normal mucosa, and found that there was a significant difference in the expression of MXRA5 between the two , But there is no study on whether MXRA5 can be used as a tumor marker of colorectal cancer. The purpose of this experiment is to explore the expression of MXRA5 in colorectal cancer and its clinical significance. Methods: The expression of MXRA5 in colorectal carcinoma was detected by immunohistochemistry and real-time quantitative PCR. The relationship between the expression of MXRA5 and clinicopathological features was analyzed. Results: The immunological scores of MXRA5 in normal colorectal tissues, adenomas and tumors were significantly different (P <0.05), and the positive expression of MXRA5 was significantly correlated with tumor stage and omentum metastasis. No significant difference was found in the expression of MXRA5 at the gene level. CONCLUSIONS: Our results confirm the abnormal expression of MXRA5 in colorectal cancers and may be tumor markers for the early diagnosis of colorectal cancer or omental metastasis.